Real-world Effectiveness of HPV Vaccine in Women Living With HIV and Its Impact on Cervical Cancer Screening Accuracies
Studying Primary immunodeficiency
Last synced from ClinicalTrials.gov
Key facts
- Sponsor
- University of California, Los Angeles
- Principal Investigator
- Anna-Barbara Moscicki, MDUniversity of California, Los Angeles
- Intervention
- Self-Collection HPV testing kit from Abbott(diagnostic_test)
- Enrollment
- 810 target
- Eligibility
- 21-40 years · FEMALE
- Timeline
- 2024 – 2028
Study locations (9)
- University of Colorado, Denver, Colorado, United States
- Univeristy of Miami, Miami, Florida, United States
- Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- Children's Hospital New Orleans, New Orleans, Louisiana, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Bronx-Lebanon Hospital Center Health Care System, The Bronx, New York, United States
- Jacobi Medical Center, The Bronx, New York, United States
- St. Jude Children's research hospital, Memphis, Tennessee, United States
- Baylor college of Medicine, Houston, Texas, United States
Collaborators
Harvard School of Public Health (HSPH) · Frontier Science & Technology Research Foundation, Inc. · Albert Einstein College of Medicine · Boston Children's Hospital · St. Jude Children's Research Hospital · University of Colorado, Denver · Bronx-Lebanon Hospital Center Health Care System · University of Miami · Baylor College of Medicine · Children's Hospital New Orleans, LA · Jacobi Medical Center · Ann & Robert H Lurie Children's Hospital of Chicago
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06144229 on ClinicalTrials.govOther trials for Primary immunodeficiency
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE4NCT07076446An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)CSL Behring
- RECRUITINGPHASE1, PHASE2NCT06839456Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCTChildren's Hospital of Philadelphia
- RECRUITINGNCT06565078A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary ImmunodeficiencyTakeda
- RECRUITINGNANCT07261891Ex Vivo Evaluation of JAK-inhibitor and Gene Therapeutical Approach in JAK-STAT Related Disordersprof. dr. Rik Schrijvers
- ACTIVE NOT RECRUITINGPHASE2NCT06549114Leniolisib for Immune Dysregulation in PIDsPharming Technologies B.V.
- RECRUITINGNANCT06659588Study of Populations at Risk of Developing Chronic Hepatitis Linked to Chronic Enteric Virus Infection in Patients With Primary Immunodeficiency and Secondary Humoral DeficiencyAssistance Publique - Hôpitaux de Paris
- RECRUITINGNANCT07004803Virtual Reality on Pain and Fear Levels of Children With Primary ImmunodeficiencyDr. Hatice Dönmez
- ENROLLING BY INVITATIONNANCT06334341A Multilevel, Multiphase Optimization Strategy for PrEP (MOST:PrEP)Henry Ford Health System